Amgen was founded in 1980 and is headquartered in Thousand Oaks, US

Chairman and Chief Executive Officer

SVP, Global Marketing and Commercial Development

Amgen has offices in Thousand Oaks, San Francisco, South San Francisco, Bucharest and in 59 other locations

Thousand Oaks, US (HQ)

One Amgen Center Drive

Amgen's revenue was reported to be $23 b in FY, 2016 which is a **6% increase** from the previous period.

Numbers are in $, USD

## Revenue (FY, 2016) | 23 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 6% |

## Gross profit (FY, 2016) | 18.8 b |

## Gross profit margin (FY, 2016), % | 82% |

## Net income (FY, 2016) | 7.7 b |

## EBIT (FY, 2016) | 9.8 b |

## Market capitalization (23-May-2017) | 113.3 b |

## Closing share price (23-May-2017) | 153 |

## Cash (31-Dec-2016) | 3.2 b |

## EV | 144.7 b |

Amgen's current market capitalization is $113.3 b.

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 18.7 b | 20.1 b | 21.7 b | 23 b |

## Revenue growth, % | 7% | 8% | 6% | |

## Cost of goods sold | 3.3 b | 4.4 b | 4.2 b | 4.2 b |

## Gross profit | 15.3 b | 15.6 b | 17.4 b | 18.8 b |

## Gross profit Margin, % | 82% | 78% | 80% | 82% |

## Operating expense total | 12.8 b | 13.9 b | 13.2 b | 13.2 b |

## EBIT | 5.9 b | 6.2 b | 8.5 b | 9.8 b |

## EBIT margin, % | 31% | 31% | 39% | 43% |

## Interest expense | 1 b | 1.1 b | 1.1 b | 1.3 b |

## Pre tax profit | 5.3 b | 5.6 b | 8 b | 9.2 b |

## Income tax expense | 184 m | 427 m | 1 b | 1.4 b |

## Net Income | 5.1 b | 5.2 b | 6.9 b | 7.7 b |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 3.8 b | 3.7 b | 4.1 b | 3.2 b |

## Accounts Receivable | 2.7 b | 2.5 b | 3 b | 3.2 b |

## Inventories | 3 b | 2.6 b | 2.4 b | 2.7 b |

## Current Assets | 27.4 b | 34.7 b | 38.5 b | 46 b |

## PP&E | 5.3 b | 5.2 b | 4.9 b | 5 b |

## Goodwill | 15 b | 14.8 b | 14.8 b | 14.8 b |

## Total Assets | 66.1 b | 69 b | 71.6 b | 77.6 b |

## Accounts Payable | 787 m | 1.2 b | 965 m | 917 m |

## Total Debt | 32.1 b | 30.7 b | 31.6 b | 34.6 b |

## Current Liabilities | 7.9 b | 7 b | 8.7 b | 11.2 b |

## Common Stock | 30.8 b | |||

## Retained Earnings | (7.6 b) | (4.6 b) | (2.1 b) | (438 m) |

## Total Equity | 28.1 b | 29.9 b | ||

## Debt to Equity Ratio | 1.1 x | 1.2 x | ||

## Debt to Assets Ratio | 0.5 x | 0.4 x | 0.4 x | 0.4 x |

## Financial Leverage | 2.5 x | 2.6 x |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 5.1 b | 5.2 b | 6.9 b | 7.7 b |

## Accounts Receivable | (38 m) | 136 m | (420 m) | (214 m) |

## Inventories | (7 m) | 327 m | 481 m | (80 m) |

## Accounts Payable | (184 m) | 405 m | (12 m) | (44 m) |

## Cash From Operating Activities | 6.3 b | 8.6 b | 9.1 b | 10.4 b |

## Purchases of PP&E | (693 m) | (718 m) | (594 m) | (738 m) |

## Cash From Investing Activities | (8.5 b) | (5.8 b) | (5.5 b) | (8.7 b) |

## Long-term Borrowings | (3.4 b) | (5.6 b) | (2.4 b) | (3.7 b) |

## Dividends Paid | (1.4 b) | (1.9 b) | (2.4 b) | (3 b) |

## Cash From Financing Activities | 2.7 b | (2.9 b) | (3.1 b) | (2.6 b) |

Numbers are in $, USD | Y, 2016 |
---|---|

## EV/EBIT | 14.8 x |

## EV/CFO | 14 x |

## Revenue/Employee | 1.2 m |

## Debt/Equity | 1.2 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | 2.6 x |

Source: 437 public H-1B filings from Amgen